Cytokine gene polymorphisms in multiple sclerosis: A meta-analysis of 45 studies including 7379 cases and 8131 controls

European Journal of Neurology

Volumn 18, Issue 7, 2011, Pages 944-951

  Nikolopoulos, G K ^a,b   Masgala, A ^c   Tsiara, C ^a   Limitsiou, O K ^b   Karnaouri, A C ^b   Dimou, N L ^b   Bagos, P G ^b  

^a Hellenic Centre for Disease Control and Prevention   (Greece)

^b UNIVERSITY OF CENTRAL GREECE   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Cytokines; Interleukin; Meta analysis; Multiple sclerosis; Single nucleotide polymorphism; Tumour necrosis factor

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79958802050     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03355.x     Document Type: Review

References (98)

1. Hafler DA. Multiple sclerosis. J Clin Invest 2004; 113: 788-794.
2. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008; 7: 852-858.
3. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol 2008; 28: 697-706.
4. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, Fernandez O. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis 2010; 29: 857-866.
5. Bagos PG, Nikolopoulos G, Ioannidis A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult Scler 2006; 12: 397-411.
6. Schwarz S, Leweling H. Multiple sclerosis and nutrition. Mult Scler 2005; 11: 24-32.
7. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010; 6: 156-166.
8. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007; 61: 504-513.
9. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61: 288-299.
10. Zuvich RL, McCauley JL, Oksenberg JR, et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010; 127: 525-535.
11. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
12. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS ONE 2009; 4: e4565.
13. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics 2008; 60: 275-286.
14. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007; 149: 217-225.
15. Dunn E, Sims JE, Nicklin MJ, O'Neill LA. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol 2001; 22: 533-536.
16. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382-384.
17. Patterson D, Jones C, Hart I, et al. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics 1993; 15: 173-176.
18. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38: 221-228.
19. di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992; 1: 450.
20. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
21. Walley AJ, Aucan C, Kwiatkowski D, Hill AV. Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case-control study. Eur J Hum Genet 2004; 12: 132-138.
22. Nikolopoulos GK, Dimou NL, Hamodrakas SJ, Bagos PG. Cytokine gene polymorphisms in periodontal disease: a meta-analysis of 53 studies including 4178 cases and 4590 controls. J Clin Periodontol 2008; 35: 754-767.
23. Kantarci OH, Schaefer-Klein JL, Hebrink DD, et al. A population-based study of IL4 polymorphisms in multiple sclerosis. J Neuroimmunol 2003; 137: 134-139.
24. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008; 226: 205-218.
25. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997; 46: 120-128.
26. Martinez Doncel A, Rubio A, Arroyo R, et al. Interleukin-10 polymorphisms in Spanish multiple sclerosis patients. J Neuroimmunol 2002; 131: 168-172.
27. Apostolaki M, Armaka M, Victoratos P, Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010; 11: 1-26.
28. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci U S A 1986; 83: 8699-8702.
29. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-560.
30. Fugger L, Morling N, Sandberg-Wollheim M, Ryder LP, Svejgaard A. Tumor necrosis factor alpha gene polymorphism in multiple sclerosis and optic neuritis. J Neuroimmunol 1990; 27: 85-88.
31. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 1995; 63: 143-147.
32. Braun N, Michel U, Ernst BP, et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996; 215: 75-78.
33. Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
34. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
35. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005; 2: e334.
36. Conn VS, Valentine JC, Cooper HM, Rantz MJ. Grey literature in meta-analyses. Nurs Res 2003; 52: 256-261.
37. Petiti DB. Meta-analysis Decision Analysis and Cost-Effectiveness Analysis. Oxford: Oxford University Press, 1994.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
40. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
41. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
42. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-2708.
43. Bagos PG, Nikolopoulos GK. Generalized least squares for assessing trends in cumulative meta-analysis with applications in genetic epidemiology. J Clin Epidemiol 2009; 62: 1037-1044.
44. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-254.
45. Ioannidis JP, Trikalinos TA. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J Clin Epidemiol 2005; 58: 543-549.
46. Quirico-Santos T, Suppiah V, Heggarty S, Caetano R, Alves-Leon S, Vandenbroeck K. Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr 2007; 65: 15-19.
47. Suppiah V, Goris A, Alloza I, et al. Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. Int J Immunogenet 2005; 32: 383-388.
48. Kirk CW, Droogan AG, Hawkins SA, McMillan SA, Nevin NC, Graham CA. Tumour necrosis factor microsatellites show association with multiple sclerosis. J Neurol Sci 1997; 147: 21-25.
49. Lucotte G, Bathelier C, Mercier G. TNF-alpha polymorphisms in multiple sclerosis: no association with -238 and -308 promoter alleles, but the microsatellite allele a11 is associated with the disease in French patients. Mult Scler 2000; 6: 78-80.
50. de Jong BA, Huizinga TW, Zanelli E, et al. Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology 2002; 59: 549-555.
51. Wirz SA, Morale MC, Marchetti B, et al. High frequency of TNF alleles -238A and -376A in individuals from northern Sardinia. Cytokine 2004; 26: 149-154.
52. Amirzargar A, Khosravi F, Dianat S, et al. Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients. Mult Scler 2007; 13: 253-255.
53. Ferri C, Sciacca FL, Grimaldi LE, et al. Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 564-565.
54. Luomala M, Lehtimaki T, Elovaara I, et al. A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. J Neurol Sci 2001; 185: 123-127.
55. Mann CL, Davies MB, Stevenson VL, et al. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol 2002; 129: 197-204.
56. Hooper-van Veen T, Schrijver HM, Zwiers A, et al. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. Mult Scler 2003; 9: 535-539.
57. Sarial S, Shokrgozar MA, Amirzargar A, et al. IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis. Iran J Allergy Asthma Immunol 2008; 7: 37-40.
58. Borzani I, Tola MR, Caniatti L, et al. The interleukin-1 cluster gene region is associated with multiple sclerosis in an Italian Caucasian population. Eur J Neurol 2010; 17: 930-938.
59. Niino M, Kikuchi S, Fukazawa T, Yabe I, Sasaki H, Tashiro K. Genetic polymorphisms of IL-1beta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J Neuroimmunol 2001; 118: 295-299.
60. Izad M, Vodjgani M, Niknam MH, et al. Cytokines genes polymorphisms and risk of multiple sclerosis. Am J Med Sci 2010; 339: 327-331.
61. Luomala M, Lehtimaki T, Huhtala H, et al. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand 2003; 108: 396-400.
62. Pickard C, Mann C, Sinnott P, et al. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J Neuroimmunol 1999; 101: 207-210.
63. Ma JJ, Nishimura M, Mine H, et al. HLA-DRB1 and tumor necrosis factor gene polymorphisms in Japanese patients with multiple sclerosis. J Neuroimmunol 1998; 92: 109-112.
64. Fernandes Filho JA, Vedeler CA, Myhr KM, Nyland H, Pandey JP. TNF-alpha and -beta gene polymorphisms in multiple sclerosis: a highly significant role for determinants in the first intron of the TNF-beta gene. Autoimmunity 2002; 35: 377-380.
65. Fernandez-Arquero M, Arroyo R, Rubio A, et al. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 1999; 53: 1361-1363.
66. Duvefelt K, Anderson M, Fogdell-Hahn A, Hillert J. A NOTCH4 association with multiple sclerosis is secondary to HLA-DR*1501. Tissue Antigens 2004; 63: 13-20.
67. Anlar B, Alikasifoglu M, Kose G, Guven A, Gurer Y, Yakut A. Tumor necrosis factor-alpha gene polymorphisms in children with multiple sclerosis. Neuropediatrics 2001; 32: 214-216.
68. Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986; 315: 1638-1642.
69. McElroy JP, Oksenberg JR. Multiple sclerosis genetics. Curr Top Microbiol Immunol 2008; 318: 45-72.
70. Holmoy T, Harbo H, Vartdal F, Spurkland A. Genetic and molecular approaches to the immunopathogenesis of multiple sclerosis: an update. Curr Mol Med 2009; 9: 591-611.
71. Perera D, Stankovich J, Butzkueven H, et al. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. J Neuroimmunol 2009; 211: 105-109.
72. Akkad DA, Hoffjan S, Petrasch-Parwez E, Beygo J, Gold R, Epplen JT. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. J Autoimmun 2009; 32: 110-115.
73. Alcina A, Fedetz M, Ndagire D, et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS ONE 2009; 4: e4137.
74. Weber F, Fontaine B, Cournu-Rebeix I, et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008; 9: 259-263.
75. Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113.
76. Ioannidis JP. Molecular bias. Eur J Epidemiol 2005; 20: 739-745.
77. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol 2006; 163: 300-309.
78. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007; 176: 1091-1096.
79. Sombekke MH, Arteta D, van de Wiel MA, et al. Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis. Mult Scler 2010; 16: 652-659.
80. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526.
81. Mustafina OE, Bakhtiiarova KZ, Mikhailova AM, et al. [Analysis of the association of allelic variants of apolypoprotein E and interleukin 1 beta genes with multiple sclerosis in ethnic Tatars]. Genetika 2008; 44: 407-413.
82. Aggelakis K, Zacharaki F, Dardiotis E, et al. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurol Sci 2010; 31: 253-257.
83. Schrijver HM, Crusius JB, Uitdehaag BM, et al. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999; 52: 595-599.
84. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000; 106: 220-227.
85. Dincic E, Zivkovic M, Stankovic A, et al. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J Neuroimmunol 2006; 177: 146-150.
86. Urcelay E, Santiago JL, Mas A, et al. Role of interleukin 4 in Spanish multiple sclerosis patients. J Neuroimmunol 2005; 168: 164-167.
87. de Jong BA, Westendorp RG, Eskdale J, Uitdehaag BM, Huizinga TW. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol 2002; 63: 281-285.
88. Myhr KM, Vagnes KS, Maroy TH, Aarseth JH, Nyland HI, Vedeler CA. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci 2002; 202: 93-97.
89. Mihailova S, Ivanova M, Mihaylova A, Quin L, Mikova O, Naumova E. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J Neuroimmunol 2005; 168: 138-143.
90. Maurer M, Kruse N, Giess R, Toyka KV, Rieckmann P. Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis. J Neuroimmunol 2000; 104: 98-100.
91. Forte GI, Ragonese P, Salemi G, et al. Search for genetic factors associated with susceptibility to multiple sclerosis. Ann N Y Acad Sci 2006; 1067: 264-269.
92. Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology 1997; 49: 626-628.
93. Mycko M, Kowalski W, Kwinkowski M, et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol 1998; 84: 198-206.
94. Maurer M, Kruse N, Giess R, Kyriallis K, Toyka KV, Rieckmann P. Gene polymorphism at position -308 of the tumor necrosis factor alpha promotor is not associated with disease progression in multiple sclerosis patients. J Neurol 1999; 246: 949-954.
95. Sotgiu S, Pugliatti M, Serra C, Rosati G, Dolei A, Marrosu MG. Tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-alpha production in Sardinian multiple sclerosis. Ann Neurol 1999; 46: 799-800.
96. Drulovic J, Popadic D, Mesaros S, et al. Decreased frequency of the tumor necrosis factor alpha -308 allele in Serbian patients with multiple sclerosis. Eur Neurol 2003; 50: 25-29.
97. Ristic S, Lovrecic L, Starcevic-Cizmarevic N, et al. Tumor necrosis factor-alpha-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur Neurol 2007; 57: 203-207.
98. Kamali-Sarvestani E, Nikseresht A, Aflaki E, Sarvari J, Gharesi-Fard B. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol Scand 2007; 115: 161-166.